1. Najar IA, Johri RK. Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide. J Biosci. 2014;39(1):139–44.
2. Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19(9):1239–46.
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–40.
4. Lyman GH, Poniewierski MS. A patient risk model of chemotherapy-induced febrile neutropenia: lessons learned from the ANC study group. J Natl Compr Canc Netw. 2017;15(12):1543–50.
5. Rabinowitz AP, Weiner NJ, Tronic BS, Fridman M, Liberman RF, Delgado DJ. Severe neutropenia in CHOP occurs most frequently in cycle 1: a predictive model. Leuk Lymphoma. 2006;47(5):853–8.